Persisting Antibody Response to SARS-CoV-2 in a Local Austrian Population

Rösgen, Delia; Schreiner, Clemens; Ladage, Dorothee; Adler, Christoph; Harzer, Oliver; Braun, Ralf J.

doi:10.3389/fmed.2021.653630

Cited by 7 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Euroimmun assay-measured antibodies against the S1 subunit of the surface glycoprotein Spike-S show a decrease in antibody titers over time. Six to nine months after initial IgG seroconversion, results indicate a maintained seropositivity between 50% and over 80% [56][57][58][59] . The maintained seropositivity of 62% after a median time of 70 days (interquartile range 33-193 days) in our study is lower, which may be due to the population sample with more asymptomatic and less severe cases than in a clinical sample.…”

Section: Discussionmentioning

confidence: 98%

Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020

Neuhauser

Rosario

Butschalowsky

et al. 2022

Sci Rep

View full text Add to dashboard Cite

Pre-vaccine SARS-CoV-2 seroprevalence data from Germany are scarce outside hotspots, and socioeconomic disparities remained largely unexplored. The nationwide representative RKI-SOEP study (15,122 participants, 18–99 years, 54% women) investigated seroprevalence and testing in a supplementary wave of the Socio-Economic-Panel conducted predominantly in October–November 2020. Self-collected oral-nasal swabs were PCR-positive in 0.4% and Euroimmun anti-SARS-CoV-2-S1-IgG ELISA from dry-capillary-blood antibody-positive in 1.3% (95% CI 0.9–1.7%, population-weighted, corrected for sensitivity = 0.811, specificity = 0.997). Seroprevalence was 1.7% (95% CI 1.2–2.3%) when additionally correcting for antibody decay. Overall infection prevalence including self-reports was 2.1%. We estimate 45% (95% CI 21–60%) undetected cases and lower detection in socioeconomically deprived districts. Prior SARS-CoV-2 testing was reported by 18% from the lower educational group vs. 25% and 26% from the medium and high educational group (p < 0.001, global test over three categories). Symptom-triggered test frequency was similar across educational groups. Routine testing was more common in low-educated adults, whereas travel-related testing and testing after contact with infected persons was more common in highly educated groups. This countrywide very low pre-vaccine seroprevalence in Germany at the end of 2020 can serve to evaluate the containment strategy. Our findings on social disparities indicate improvement potential in pandemic planning for people in socially disadvantaged circumstances.

show abstract

Section: Discussionmentioning

confidence: 98%

Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020

Neuhauser

Rosario

Butschalowsky

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Euroimmun assay-measured antibodies against the S1 subunit of the surface glycoprotein Spike-S show a decrease in antibody titers over time. Six to nine months after initial IgG seroconversion, results indicate a maintained seropositivity between 50% and over 80% [57][58][59][60] . The maintained seropositivity of 62% after a median time of 70 days (interquartile range 33-193 days) in our study is lower which may be due to the population sample with more asymptomatic cases.…”

Section: Discussionmentioning

confidence: 98%

Germany’s low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study

Neuhauser

Rosario

Butschalowsky

et al. 2021

Preprint

View full text Add to dashboard Cite

Pre-vaccine SARS-CoV-2 seroprevalence data from Germany are scarce outside hotspots, and socioeconomic disparities remained largely unexplored. The nationwide RKI-SOEP study with 15,122 adult participants investigated seroprevalence and testing in a supplementary wave of the Socio-Economic-Panel conducted predominantly in October-November 2020. Self-collected oral-nasal swabs were PCR-positive in 0.4% and Euroimmun anti-SARS-CoV-2-S1-IgG ELISA from dry capillary blood in 1.3% (95% CI 0.9-1.7%, population-weighted, corrected for sensitivity=0.811, specificity=0.997). Seroprevalence was 1.7% (95% CI 1.2-2.3%) when additionally adjusting for antibody decay. Overall infection prevalence including self-reports was 2.1%. We estimate 45% (95% CI 21-60%) undetected cases and analyses suggest lower detection in socioeconomically deprived districts. Prior SARS-CoV-2 testing was reported by 18% from the lower educational group compared to 25% and 26% from the medium and high educational group (p<0.0001). Symptom-triggered test frequency was similar across educational groups. However, routine testing was more common in low-educated adults, whereas travel-related testing and testing after contact with an infected person was more common in highly educated groups. In conclusion, pre-vaccine SARS-CoV-2-seroprevalence in Germany was very low. Notified cases appear to capture more than half of infections but may underestimate infections in lower socioeconomic groups. These data confirm the successful containment strategy of Germany until winter 2020.

show abstract

“…Similarly, a reduction of antibody response in asymptomatic individuals was shown in a study with a fewer number of individuals ( n = 37) 5 . In another study with a small number of subjects ( n = 68), both IgG and IgA were shown to remain remarkably high for a 4 month period of time 6 . The antibody response in COVID-19 patients is associated with the establishment of a memory B cell response which is higher at 6 months 1 , however, it is not clear whether there are features that correlate with this sustained B cell response.…”

Section: Introductionmentioning

confidence: 91%

The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients

et al. 2021

View full text Add to dashboard Cite

Background Persistence of antibodies to SARS-CoV-2 viral infection may depend on several factors and may be related to the severity of disease or to the different symptoms. Methods We evaluated the antibody response to SARS-CoV-2 in personnel from 9 healthcare facilities and an international medical school and its association with individuals’ characteristics and COVID-19 symptoms in an observational cohort study. We enrolled 4735 subjects (corresponding to 80% of all personnel) for three time points over a period of 8–10 months. For each participant, we determined the rate of antibody increase or decrease over time in relation to 93 features analyzed in univariate and multivariate analyses through a machine learning approach. Results Here we show in individuals positive for IgG (≥12 AU/mL) at the beginning of the study an increase [p = 0.0002] in antibody response in paucisymptomatic or symptomatic subjects, particularly with loss of taste or smell (anosmia/dysgeusia: OR 2.75, 95% CI 1.753 – 4.301), in a multivariate logistic regression analysis in the first three months. The antibody response persists for at least 8–10 months. Conclusions SARS-CoV-2 infection induces a long lasting antibody response that increases in the first months, particularly in individuals with anosmia/dysgeusia. This may be linked to the lingering of SARS-CoV-2 in the olfactory bulb.

show abstract

Persisting Antibody Response to SARS-CoV-2 in a Local Austrian Population

Cited by 7 publications

References 14 publications

Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020

Nationally representative results on SARS-CoV-2 seroprevalence and testing in Germany at the end of 2020

Germany’s low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study

The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients

Contact Info

Product

Resources

About